94,400 Shares in Qiagen N.V. $QGEN Acquired by Lingohr Asset Management GmbH

Lingohr Asset Management GmbH bought a new position in Qiagen N.V. (NYSE:QGEN) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 94,400 shares of the company’s stock, valued at approximately $4,218,000.

Several other hedge funds have also added to or reduced their stakes in the business. MAI Capital Management boosted its stake in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after buying an additional 849 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after purchasing an additional 796 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after acquiring an additional 980 shares during the last quarter. Finally, Cullen Frost Bankers Inc. lifted its stake in shares of Qiagen by 13,144.4% in the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock worth $57,000 after buying an additional 1,183 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Price Performance

QGEN stock opened at $53.63 on Friday. Qiagen N.V. has a 1 year low of $39.61 and a 1 year high of $57.81. The business’s 50-day moving average is $49.53 and its two-hundred day moving average is $49.64. The firm has a market capitalization of $11.33 billion, a P/E ratio of 27.69, a P/E/G ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, November 6th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. The firm had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on QGEN. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $57.89 to $52.63 in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft downgraded Qiagen from a “buy” rating to a “hold” rating and boosted their target price for the stock from $52.00 to $54.00 in a research note on Thursday, January 22nd. Finally, UBS Group reaffirmed a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Qiagen presently has an average rating of “Hold” and a consensus target price of $53.04.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.